Abstract
Background/Aim: Hepcidin is a cationic acute phase reactant synthesized by the liver. It has bactericidal properties and is a major regulator of iron homeostasis. Cationic antimicrobial peptides represent an innate antimicrobial defense system. We hypothesized that, like other cationic antimicrobial peptides, hepcidin is cytotoxic to cancer cells. Materials and Methods: The cytotoxicity of human hepcidin against myeloma cells was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and DNA fragmentation assays. Plasma membrane damage was quantified by propidium iodide (PI) staining. Cell membrane changes were visualized by scanning electron microscopy. Results: Hepcidin impaired myeloma cell survival and induced DNA fragmentation. PI staining and scanning electron microscopy revealed hepcidin-induced disruption of the plasma membrane. Conclusion: Human hepcidin is an anti-cancer peptide that induces myeloma cell lysis, and therefore may play a role in innate anticancer immunity. To our knowledge, this is the first biological function ascribed to human hepcidin that is not related to its antimicrobial and iron-regulatory properties.
- Myeloma
- hepcidin
- DNA fragmentation
- membrane damage
- cell death
Multiple myeloma is the second leading cause of death from hematological malignancies (1). Despite ongoing research and development in cancer therapeutics, multiple myeloma largely remains an incurable disease (2, 3). By virtue of its slow growth, myeloma is refractory to chemotherapy agents that are most effective against rapidly dividing cancer cells (4). Newer therapies for myeloma, such as daratumumab, are thought to kill myeloma cells by multiple mechanisms, including cell lysis (5-7).
Cationic antimicrobial peptides represent an innate antimicrobial defense system that exerts immunomodulatory effects and antimicrobial activity against both Gram-negative and Gram-positive bacteria, as well as fungi, protozoa, and viruses (8-13). Recent studies suggest that some cationic antimicrobial peptides contribute to innate anticancer immunity and are, thus, termed anticancer peptides (ACPs). ACPs are able to kill cancer cells while leaving normal cells virtually unaffected (14-16). This apparent selectivity towards cancer cells is thought to be due to cell membrane charge differences between neoplastic and normal cells (17). The positive charge of ACPs allows them to interact with the negatively charged cytoplasmic membrane of cancer cells, regardless of their rate of cellular division (16). The mechanisms by which ACPs subsequently mediate cancer cell death include loss of cell membrane integrity and/or disruption of the mitochondrial membrane with release of cytochrome C, accumulation of reactive oxygen species, and induction of apoptosis (15, 16, 18-21). Importantly, ACPs are equally effective at killing rapidly and slowly growing cancers, in addition to chemoresistant cancer cells (15, 22, 23).
Hepcidin is a 25-amino acid cationic antimicrobial peptide produced by hepatocytes as part of the acute phase response (24). Hepcidin is involved in iron homeostasis; its expression is increased during inflammation, resulting in anemia of chronic disease (25). In addition, hepcidin negatively regulates iron absorption in the small bowel, transplacental iron transport, and the release of iron from macrophages. These effects are mediated by hepcidin’s negative regulation of ferroportin, the major iron exporter of vertebrates (26). Transcription of the hepcidin gene is up-regulated in response to several stimuli, including proinflammatory cytokines (27-29), and serum levels of hepcidin increase after lipopolysaccharide injection into healthy volunteers (30). Increased concentrations of circulating hepcidin have been reported in anemia in the context of inflammatory states, likely accounting for the sequestration of iron in macrophages that is seen in these conditions (25, 31). Elevated serum hepcidin levels have been observed in the setting of numerous cancers, including plasma cell myeloma (32). Interestingly, patients with low levels of hepcidin, as occurs in hereditary hemochromatosis, thalassemia, and iron deficiency anemia, have an increased risk of cancer (33-36).
Plasma cell myeloma is an indolent cancer that is generally refractory to conventional chemotherapy and without cure (2, 3). Little is known about the effect of ACPs on myeloma cells, although a previous study from our lab shows that myeloma cell lines are sensitive to the cytotoxic effects of at least some ACPs (14). We hypothesized that human hepcidin would be cytotoxic to myeloma cells in vitro and therefore act as an ACP. We believe that elevated concentrations of hepcidin in the context of cancer may reflect a previously unappreciated aspect of innate anticancer immunity in humans (37).
Materials and Methods
Hepcidin. Hepcidin-20 was purchased from American Peptide Company (Sunnyvale, CA, USA). This 20-amino acid peptide isoform of human hepcidin, which lacks the ability to regulate iron (38), was used in this study so that only iron-independent effects of hepcidin would be observed. Concentrated stock solutions of hepcidin dissolved in phosphate-buffered saline (PBS; Sigma-Aldrich Canada, Oakville, ON, Canada) were aliquoted and stored at –80°C.
Cell culture and conditions. Human U266 myeloma cells were kindly provided by Dr. Tony Reiman (Saint John Regional Hospital, Saint John, NB, Canada), mouse HOPC myeloma cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Melphalan-resistant U266 cells were passaged weekly in 10 μM melphalan (Sigma-Aldrich Canada). All cell lines were maintained at 37°C in a 5% CO2 humidified atmosphere in RPMI-1640 medium (Sigma-Aldrich Canada) supplemented with 5% heat-inactivated fetal bovine serum (FBS), 5 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] (pH 7.4), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Burlington, ON, Canada). Peptide experiments were conducted with complete medium containing 0.5% FBS.
Cell viability assay. Cell viability assays were performed to assess the effect of human hepcidin against mouse and human myeloma cells by measuring metabolic activity. U266 cells or HOPC cells were seeded in quadruplicate at 5×104 cells/well into 96-well flat-bottomed tissue culture plates (Sarstedt, St. Leonard, QC, Canada) and treated with medium/PBS vehicle alone or human hepcidin at 25, 50, and 100 μM for 24 h. In other experiments, melphalan-resistant U266 cells were cultured in the absence or presence of 100 μM of human hepcidin for 24 h. For the last 2 h of culture, 0.1 mg 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) was added to cell cultures. Formazan crystals were solubilized in 100 μl/well dimethyl sulfoxide (DMSO) and absorbance (490 nm) was measured using a Bio-Tek microplate reader (Bio-Tek Instruments, Winooski, VT, USA). Average percent metabolic activity was calculated by the formula: (optical density of treatment/optical density of no treatment control) ×100 as previously described (15).
Propidium iodide assay. Propidium iodide (PI) uptake was measured by flow cytometry to assess cell membrane damage induced by hepcidin. U266 or HOPC cells were treated with vehicle or 100 μM hepcidin for 30 min and 2 h. Cells were then stained with 5 μg/ml PI (Invitrogen) for 5 min, washed, and PI uptake was quantified with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
DNA fragmentation assay. The effect of hepcidin on the integrity of DNA in U266 and HOPC cells was determined using a DNA-fragmentation assay (39). Cells were labelled with 0.25 μCi of tritiated thymidine ([3H]-TdR; MP Biomedicals LLC, Santa Ana, CA, USA), washed, and seeded in quadruplicate at 5×104 cells/well into 96-well U-bottom cell culture plates. Cells were cultured in the absence or presence of 100 μM of hepcidin for 2, 6, and 24 h. Cells were then harvested onto glass fiber mats using a Skatron multiple sample harvester and [3H]-TdR recovery was determined by liquid scintillation counting. Data are expressed as % DNA fragmentation, which was determined as follows:
% DNA fragmentation for treated cells=(1-[cpm from treated cells]/[cpm from PBS-treated cells]) ×100.
Scanning electron microscopy. Scanning electron microscopy was used to assess U266 and HOPC cell membrane changes following exposure to hepcidin. Cells were grown on sterile circular poly-L-lysine-coated coverslips with vehicle (PBS) or 100 μM of hepcidin for 30 min and 2 h. Cells were then fixed with glutaraldehyde (2.5% [v/v] in 0.1 M sodium cacodylate), washed with 0.1 M sodium cacodylate, fixed with osmium tetroxide (1% [w/v] in 0.1 M sodium cacodylate) for 30 min, washed, and dehydrated in increasing concentrations of ethanol. Prepared cells were dried to their critical point using a Polaron E3000 Critical Point Dryer (Quorum Technologies, Guelph, ON, Canada), mounted, and coated with gold using a Polaron SC7620 Mini Sputter Coater (Quorum Technologies). Cells were viewed at 500×, 7 000× and 40 000× magnification using a Hitachi S4700 scanning electron microscope (Hitachi High Technologies, Rexdale, ON, Canada).
Statistical analysis. GraphPad Prism 7.0 was used to perform one-way ANOVA with Tukey post-test on data from at least three independent experiments. Statistical significance was identified as p<0.05.
Results
Hepcidin reduces the metabolic activity of myeloma cells. MTT assays were used to determine the effect of hepcidin on myeloma cell viability, as indicated by altered metabolic activity. Figure 1 shows that hepcidin reduced the metabolic activity of human U266 (Figure 1A) and mouse HOPC (Figure 1B) myeloma cell lines in a concentration-dependent manner. To our knowledge, this is the first report of human hepcidin possessing anticancer properties. Interestingly, PC3 human prostate and HT-29 human colorectal cancer cells were not killed by hepcidin (data not shown). Melphalan is an alkylating chemotherapeutic agent that is used to treat plasma cell myeloma (40). However, current chemotherapeutic drugs have limited effectiveness against plasma cell myeloma, in part due to their inability to kill multidrug-resistant cancer cells (2, 3). A 100 μM concentration of hepcidin was cytotoxic for melphalan-resistant U266 cells (vehicle, 93±4% metabolic activity relative to the medium control; hepcidin, 45±10% metabolic activity relative to the medium control, p<0.05; n=3).
Hepcidin causes substantial cell membrane damage to myeloma cells. Flow cytometric analysis of cellular PI uptake was used to measure myeloma cell plasma membrane damage following exposure to hepcidin. As shown in Figure 2, hepcidin caused substantial PI uptake in both human U266 (Figure 2A and B) and mouse HOPC (Figure 2C and D) myeloma cells. Representative histograms of fluorescence are shown in Figure 2A and C, whereas average fluorescence is shown in Figure 2B and D. Scanning electron microscopy was used to visualize cell membrane changes in the presence of hepcidin. The resulting images confirmed that exposure to hepcidin damaged the cell membrane of human (Figure 3A) and mouse (Figure 3B) myeloma cells by causing extensive pore formation.
Hepcidin triggers DNA fragmentation in myeloma cells. Figure 4 shows that after only 2 h, exposure to hepcidin caused human U266 (Figure 4A) and mouse HOPC (Figure 4B) myeloma cells to experience extensive DNA fragmentation. By 24 h, DNA fragmentation was almost complete, indicating a time-dependent effect.
Discussion
The acute phase protein hepcidin possesses antimicrobial properties afforded by its overall positive charge. Numerous antimicrobial peptides are also endowed with anticancer properties imparted by their positive charge, which allows them to preferentially interact with negatively charged cancer cell membranes. Our study provides the first evidence that human hepcidin kills myeloma cells, and thus also behaves as an anticancer peptide (ACP). The cytotoxic effect of hepcidin was both concentration- and time-dependent, mediated by its ability to induce pore formation in the myeloma cell plasma membrane (Figures 2 and 3). This lytic mechanism of hepcidin-induced cancer cell death is similar to the bactericidal effect of hepcidin against uropathogenic Escherichia coli (41). Many other ACPs have likewise been shown to cause substantial damage to the plasma membrane of cancer cells (15, 19-21). This mechanism of action contrasts with the ACP bovine lactoferricin, which has a minimal effect on cancer cell membrane integrity but rather enters the cancer cell and induces apoptosis and subsequent DNA fragmentation by targeting mitochondrial membranes (18). It is likely that hepcidin-induced DNA fragmentation is also the result of damage to the mitochondria and subsequent caspase activation that occurs after already lethal cell membrane damage has occurred. Given the severe damage to the plasma membrane of myeloma cells after 30 min exposure to hepcidin, it follows that DNA fragmentation may be a secondary effect that does not substantially contribute to hepcidin-mediated cytotoxicity against myeloma cells.
Melphalan-resistance in myeloma cells is attributed to antioxidant defenses (42), as well as alterations in cell signaling and nuclear localization of survival-promoting nuclear factor-ĸB (NF-ĸB) and survivin (43). These mechanisms would be protective against programmed cell death, due to interference with the complex signaling processes that mediate apoptosis. However, hepcidin-induced myeloma cell death is initiated by extensive disruption of plasma membrane integrity, resulting in mechanical cell lysis that is equally toxic to melphalan-resistant and melphalan-naïve myeloma cells. Other ACPs have also shown activity against chemoresistant cancer cells (15, 22, 23), although the mechanism of action is not yet clear.
Preferential toxicity to myeloma cells compared to PC3 human prostate and HT-29 human colorectal cancer cells may be due to a greater concentration of negatively charged amino acids on the myeloma cell surface. For example, myeloma cells express high levels of CD38, which contains many negative amino acid residues (44). Myeloma stem cells are primitive slow-growing myeloma progenitor cells that are resistant to therapy and are thus believed to contribute to the incurable nature of plasma cells myeloma (45). However, because stem cells also bear a negative membrane charge (46), hepcidin and other ACPs may represent a promising therapeutic option for elimination of myeloma stem cells.
Hepcidin is best known as a regulator of iron metabolism (25). The ability of hepcidin to reduce iron levels in the inflammatory setting of cancer likely inhibits neoplastic cell growth (47). Manipulating iron transport decreases cancer cell growth (48). As our study exclusively made use of the 20-amino acid isoform of hepcidin that lacks the N-terminal iron regulatory domain (38), its cytotoxic effect on myeloma cells was de facto iron-independent. Our findings suggest that hepcidin may contribute to innate anticancer immunity, by virtue of its ability to interact with and disrupt negatively charged cancer cell membranes. The concentrations of hepcidin that were cytotoxic for myeloma cells are similarly reported for in vitro antimicrobial concentrations (41), both of which are higher than hepcidin levels measured in healthy individuals (49) and in individuals with plasma cell myeloma (23). Interestingly, in a lower pH environment the concentration of hepcidin required to kill bacteria is decreased (50). Acidic tumor microenvironments may therefore enhance the effectiveness of hepcidin-induced cell death, such that physiologic concentrations of hepcidin are lethal to cancer cells (51).
Our findings, taken together with the increased levels of hepcidin reported in the circulation of multiple myeloma patients (32), suggest that hepcidin is part of the innate immune response to this hematological malignancy. Hepcidin is induced in multiple myeloma by increased bone morphogenetic protein 2 and IL-6 (52), decreasing ferroportin expression and leading to anemia (53). Limiting iron availability is one potential way that hepcidin could limit myeloma growth, in addition to its direct cytotoxic activity. Effective treatment of multiple myeloma decreases the hepcidin levels in patients (54). Hepcidin may also contribute to innate immune response to other types of cancer since hepcidin levels are increased in colorectal cancer (55), breast cancer (56), lung cancer (57), and pancreatic cancer (58). This would explain the increased risk of cancer in individuals with hereditary hemochromatosis, thalassemia, and iron deficiency anemia, all of which are associated with reduced hepcidin expression. Hepcidin may therefore be a prognostic indicator for both hematological and nonhematological malignancies (56-58). Natural cancer defense has been observed in humans and other animals (59), including p53-dependent upregulation of hepcidin (60). However, additional study is required to fully understand the physiological role of hepcidin in multiple myeloma. Nevertheless, hepcidin warrants further investigation as a potential therapeutic for the treatment of multiple myeloma.
Acknowledgements
This research was funded by the Acadia University Research Fund (M.C.), the Breast Cancer Society of Canada (D.H.), the Canadian Cancer Society/Canadian Breast Cancer Foundation (D.H.), the Capital Health Research Fund (D.C.), the Michael Smith Foundation for Health Research (A.H.), the Natural Sciences and Engineering Research Council (A.H. and K.M.), Research Nova Scotia (K.M.), and the Raddall Fund (M.C.).
Footnotes
Authors’ Contributions
D.C., A.H., R.L., D.H., and M.C.: Conception and study design; D.C., A.H., and M.C.: Collection of data; D.C., A.H., K.M., D.H., and M.C.: Analysis and interpretation of data; D.C., K.M., D.H., and M.C.: drafting of the article; and revision of the article. All Authors approved the final version of the article.
This article is freely accessible online.
Conflicts of Interest
The Authors declare no conflicts of interest.
- Received October 31, 2020.
- Revision received January 4, 2021.
- Accepted January 7, 2021.
- Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.